vidarabine has been researched along with Extravascular Hemolysis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calixto, R; Chandrasekaran, V; Domingues, MC; Florêncio, R; Maior, AP; Ostronoff, F; Ostronoff, M; Sucupira, A | 1 |
| Fay, M; Murphy, PT; Nolan, A; O'Donnell, R; Quinn, J; Swords, R | 1 |
| Azar, N; Binet, JL; Dighiero, G; Gabarre, J; Gonzalez, H; Leblond, V; Sutton, L; Vernant, JP | 1 |
3 other study(ies) available for vidarabine and Extravascular Hemolysis
| Article | Year |
|---|---|
Immune hemolysis after fludarabine-based reduced intensity conditioning and allogeneic PBSC transplantation for CML with minor ABO incompatibility.
Topics: Antineoplastic Agents; Blood Group Incompatibility; Female; Hemolysis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Hemolysis; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Vidarabine | 2006 |
Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Hemolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Rate; Time Factors; Vidarabine | 1998 |